Amgen (AMGN) Tops Q1 Earnings and Revenue Estimates

Core Viewpoint - Amgen reported quarterly earnings of $4.90 per share, exceeding the Zacks Consensus Estimate of$ 4.16 per share, and showing an increase from $3.96 per share a year ago, representing an earnings surprise of 17.79% [1][2] Financial Performance - The company achieved revenues of$ 8.15 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.47%, and up from $7.45 billion year-over-year [2] - Over the last four quarters, Amgen has exceeded consensus EPS estimates four times and topped revenue estimates three times [2] Stock Performance - Amgen shares have increased approximately 11.6% since the beginning of the year, contrasting with a decline of -5.3% in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is$ 5.29 on revenues of $8.82 billion, and for the current fiscal year, it is$ 20.57 on revenues of $34.99 billion [7] - The outlook for the Medical - Biomedical and Genetics industry is favorable, ranking in the top 32% of over 250 Zacks industries, suggesting potential for outperformance [8]